A Phase 2 interventional study of Biospecimen Collection and Chest Radiography in AIDS-Related Kaposi Sarcoma and Skin Kaposi Sarcoma, sponsored by AIDS Malignancy Consortium. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by AIDS Malignancy Consortium · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium — 2 open to participants now, 2 under way, 1 of them phase 3. AIDS-related Kaposi sarcoma · AIDS Malignancy Consortium.
Among the 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium, this one is one of 2 that started in 2026, is one of 4 in phase 2, and was the 12th registered.
43 studies on the registry are indexed under AIDS-related Kaposi sarcoma; 2 are open to participants now.
Browse AIDS-related Kaposi sarcoma studies →2 of the 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium are open now, in 1 country. Recruiting first, the newest first:
AIDS Malignancy Consortium
Ages 18+
By country, each count listing its studies:
Of the 1 AIDS-related Kaposi sarcoma study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 1
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is close to the median of 30 across 28 interventional studies indexed under AIDS-related Kaposi sarcoma.
Median enrollment 18 across the 8 interventional studies, 47 across the 3 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
AIDS Malignancy Consortium is the lead sponsor of 61 studies on the registry; 9 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other proteins called Notch receptors. Blocking these proteins may help keep tumor cells from growing and may kill them. Nirogacestat is a type of gamma secretase inhibitor. Nirogacestat may be effective in shrinking the size of KS lesions and reducing the spread of lesions.
PRIMARY OBJECTIVE:
I. Evaluate the efficacy of nirogacestat in terms of overall response (partial response [PR]) or complete response [CR]) of Kaposi sarcoma (KS) tumors.
SECONDARY OBJECTIVES:
I. Evaluate the safety and tolerability of nirogacestat. II. Evaluate the duration of response of KS tumors to nirogacestat. III. Assess the effect of nirogacestat on blood biomarkers such as CD4+ and CD8+ T, CD19+, cell number, human immunodeficiency virus (HIV) and Kaposi sarcoma-associated herpesvirus (KSHV) virus load.
IV. Assess baseline levels of Notch target and regulatory gene products as a target of nirogacestat activity.
EXPLORATORY OBJECTIVES:
I. Assess the effect of nirogacestat on tumor-associated KSHV latent and lytic gene expression.
II. Assess effects of nirogacestat on activation of Notch target genes and Notch regulatory genes.
III. Assess effects of nirogacestat on tumor-associated endothelial-mesenchymal transition.
IV. Assess the pharmacology of nirogacestat in KS patients. V. Assess effects of nirogacestat on tissue biomarkers at progression by single cell transcriptomics or single cell RNA sequencing (scRNAseq).
VI. Assess effects of nirogacestat on tissue biomarkers by multiplex immunohistochemistry (IHC) at baseline and after 28 days of therapy.
OUTLINE:
Patients receive nirogacestat orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo skin biopsy and chest X-ray during screening as well as blood sample collection throughout the study. Patients may also undergo an additional optional skin biopsy on study and computed tomography (CT) throughout the study.
After completion of study treatment, patients are followed every 6 months for 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females of (FCBP) must have a negative serum or urine pregnancy test defined as serum Estradiol (E2) > 30 pg/mL, a serum follicle stimulating hormone (FSH) \< 40 mIU/L (measured on Day 3 in regularly menstruating females and age-matched), within 10-14 days prior and again within 24 hours of starting nirogacestat. FCBP must either commit to continued abstinence from heterosexual intercourse or the use of two acceptable methods of , one highly effective method except oral contraceptives and one additional effective method at the same time , at the start of therapy to 7 days after discontinuation of nirogacestat, inclusive. Females and males of will be advised to use effective contraception during treatment with nirogacestat and for 7 days after the last dose. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Patients must, in the opinion of the investigator, be capable of complying with the protocol.
If HIV positive, documentation of HIV-1 or HIV-2 infection by means of any one of the following:
Exclusion Criteria:
Patient is ≤ 2 years free of another primary . Exceptions include the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive nirogacestat PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo skin biopsy and chest X-ray during screening as well as blood sample collection throughout the study. Patients may also undergo an additional optional skin biopsy on study and CT throughout the study.
Procedure: Biospecimen Collection · Procedure: Chest Radiography · Procedure: Computed Tomography · Drug: Nirogacestat · Procedure: Skin Biopsy
Undergo collection of blood
Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo chest X-ray
Also known as: Chest X-ray
Undergo CT
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography
Given PO
Also known as: (S)-2-(((S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide, PF 03084014, PF-03084014, PF03084014
Undergo skin biopsy
Also known as: Biopsy of Skin
Overall response rate (ORR)
The ORR will be estimated for each dose group and for all groups combined. The 95% confidence intervals will be constructed for the ORR.
Time frame: Up to 5 years after completion of study treatment
Incidence of adverse events (AEs)
The AEs will be tabulated by type, grade, and attribution.
Time frame: Up to 5 years after completion of study treatment
Duration of the response (DOR)
Non-responders will be excluded in DOR analysis. Participants who begin treatment but drop out prior to the first post-baseline response assessment will be considered non-responders. The Kaplan-Meier method will be used to describe the DOR for all treated participants. The proportional hazards model will be used to evaluate the association of HIV status and pretreatment status on the DOR.
Time frame: From the first date on which a partial response or complete response is documented until progression or death due to any cause, assessed up to 5 years after completion of study treatment
Cumulative proportion of study participants still in response
Will be estimated using the point estimate and the 95% confidence interval using Greenwood's formula for the standard error of the Kaplan-Meier estimate.
Time frame: At 1 year
Blood biomarkers
Will assess the effect of nirogacestat on blood biomarkers such as CD4+ and CD8+ T, CD19+, cell number, HIV and Kaposi sarcoma-associated herpesvirus virus load. The analysis of variance will be used to evaluate the changes from entry to 4 or 12 weeks in CD4 and CD8 cell counts and percentages and levels of plasma-associated HIV-1 ribonucleic acid (RNA). Descriptive statistics for biomarkers will be reported using mean, standard deviation, median, and range. Linear regression analysis and correlation coefficient analysis will be performed to examine the association between change from baseline in a specific biomarker and study covariates.
Time frame: Up to 5 years after completion of study treatment
Levels of Notch target and regulatory gene products
Will assess baseline levels of Notch target and regulatory gene products as a target of Nirogacestat activity. Notch target and regulatory gene expression at baseline will be summarized using descriptive statistics, and data visualization will be performed using principal component analysis and T-distributed stochastic neighbor embedding (t-SNE) plots. Linear and generalized linear models will be used to examine the association between expression level and study covariates. When multiplicity adjustment is needed, Bonferroni correction and false discovery rate approaches will be considered.
Time frame: Baseline up to 5 years after completion of study treatment
Tumor-associated Kaposi sarcoma-associated herpesvirus (KSHV) latent and lytic gene expression
Will assess the effect of Nirogacestat on tumor-associated KSHV latent and lytic gene expression. To evaluate the relationship between clinical response and quantitative measures of KSHV/human herpesvirus (HHV)-8 and HIV viral load, these measures will be tested to determine if they are normally distributed. If the data does not meet the assumptions of normality, the data will be transformed for analysis purposes. Analysis of variance will be used to assess the relationship between qualification of baseline levels of KSHV/HHV-8, HIV viral load, and response. Spearman rank correlation analysis will be used to evaluate the relationship between the qualification of baseline KSHV/HHV-8, HIV viral load and time to progression, and response duration.
Time frame: Up to 5 years after completion of study treatment
Activation of Notch target genes and Notch regulatory genes
Will assess effects of Nirogacestat on activation of Notch target genes and Notch regulatory genes.
Time frame: Up to 5 years after completion of study treatment
Tumor-associated endothelial-mesenchymal transition
Will assess effects of Nirogacestat on tumor-associated endothelial-mesenchymal transition. Endothelial-mesenchymal transition will be assessed from scRNAseq. The following markers will be measured. Endothelial markers decreasing over time: CDH5 (VE-cadherin), PECAM1 (CD31), VWF (von Willebrand Factor), TEK (TIE2); Mesenchymal markers increasing over time: ACTA2 (a-SMA), VIM (vimentin), S100A4 (FSP-1), FN1 (Fibronectin); Master regulators of EMT increasing over time: SNAI1 (Snail), SNAI2 (Slug), TWIST1, ZEB1, ZEB2, LEF1.
Time frame: At the end of Cycle 1 (each cycle is 28 days)
Peak plasma of Nirogacestat in KS patients
For pharmacokinetic analysis, 20 samples will be used (10 from responders and 10 from non-responders) to estimate peak plasma level.
Time frame: Cycle 1 pre-dose, 0.5, 1.5, and 3 hours post-first dose and Cycle 2 day 1, pre-dose (one cycle=28 days)
AUCs of Nirogacestat in KS patients
For pharmacokinetic analysis, 20 samples will be used (10 from responders and 10 from non-responders) to estimate area under the curve (AUC)s such as AUC0-last and AUC0-∞, clearance, half-life, time of maximum concentration, and concentration maximum.
Time frame: Cycle 1 pre-dose, 0.5, 1.5, and 3 hours post-first dose and Cycle 2 day 1, pre-dose (one cycle=28 days)
Tissue biomarkers at progression by single cell transcriptomics or single cell RNA sequencing (scRNAseq)
Will assess effects of Nirogacestat on tissue biomarkers at progression by single cell transcriptomics or scRNAseq. Descriptive statistics will be used for results of scRNAseq for 20 samples (10 samples from responders and 10 samples from non-responders). Differential expression analysis will be performed and visualization using volcano plot, boxplot, t-SNE will be displayed.
Time frame: Up to 5 years after completion of study treatment
Tissue biomarkers by multiplex immunohistochemistry (IHC)
Will assess effects of Nirogacestat on tissue biomarkers by multiplex IHC. Descriptive statistics will be used for results of multiplex IHC for 20 samples (10 samples from responders and 10 samples from non-responders). Differential expression analysis will be performed and visualization using volcano plot, boxplot, t-SNE will be displayed. For multiplexed IHC analysis, mean fluorescent intensity for each biomarker will be obtained by time point and change from baseline will be calculated and summarized using descriptive statistics.
Time frame: Baseline and after 28 days of therapy
Started Oct 2026 (actual). Primary completion is estimated for Feb 2030, 40 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirogacestat
AIDS Malignancy Consortium